RxDoctor Payments Data

Punit Agrawal, DO

Neurology · Dublin, OHNPI 1578787990

Payments from drug & device makers

$35,816in general payments, 2019–2025

Across 789 payments — averaging $45.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acorda Therapeutics, Inc$17K
  • Biogen$6K
  • Teva Pharmaceuticals USA, Inc.$973
  • AbbVie$891
  • Amgen$668
  • Sunovion Pharmaceuticals Inc.$574
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$1,4134%
  • Speaking & faculty fees$19,97456%
  • Travel & lodging$9383%
  • Food & beverage$13,30537%
  • Education$1861%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acorda Therapeutics, Inc25$16,858
Biogen27$5,932
Teva Pharmaceuticals USA, Inc.35$973
AbbVie(2 entities)68$891
Amgen(2 entities)33$668
Sunovion Pharmaceuticals Inc.41$574
UCB, Inc.30$485
EMD Serono, Inc.24$462
Neurocrine Biosciences, Inc.19$452
Amneal Pharmaceuticals LLC25$450
Lundbeck LLC26$426
Eisai Inc.24$408
Acadia Pharmaceuticals Inc23$373
Kyowa Kirin, Inc.23$365
Novartis19$344
Supernus Pharmaceuticals, Inc.29$333
Biohaven Pharmaceutical Holding Company Ltd.30$331
Adamas Pharmaceuticals, Inc.19$322
Johnson & Johnson17$295
Sanofi11$281
Lilly USA, LLC16$262
Neurelis, Inc.8$251
Medtronic(2 entities)6$244
Bristol Myers Squibb12$223
Avanir Pharmaceuticals, Inc.14$213
Upsher-smith Laboratories LLC12$213
AstraZeneca12$198
Greenwich Biosciences, Inc.11$192
Alnylam Pharmaceuticals Inc.8$192
SK Life Science, Inc.10$180
Biohaven Pharmaceuticals, Inc.12$169
Genentech USA, Inc.9$167
CSL Behring9$157
Mallinckrodt Hospital Products Inc.9$157
Avion Pharmaceuticals7$123
Merz North America, Inc.7$122
Merz Pharmaceuticals, LLC7$113
Abbott5$104
Argenx US, Inc.5$93
Jazz Pharmaceuticals Inc.5$88
Mallinckrodt Enterprises LLC3$86
Tanabe Pharma America, Inc.5$85
Currax Pharmaceuticals LLC6$82
E.r. Squibb & Sons, L.L.C.2$79
Dynasplint Systems Inc.1$73
Arbor Pharmaceuticals, Inc.3$70
Aquestive Therapeutics, Inc.2$68
Ipsen Biopharmaceuticals, Inc4$65
Zyla Life Sciences, Inc.4$59
Livanova USA, Inc.2$50
Boston Scientific2$39
Sumitomo Pharma America, Inc.2$36
Pfizer2$33
Almatica Pharma LLC2$32
MDD US Operations, LLC2$27
Vertical Pharmaceuticals, LLC2$27
Alfasigma USA, Inc.2$26
GE HealthCare1$23
Otsuka America Pharmaceutical, Inc.1$22
Banner Life Sciences, LLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,816 in reported general payments places this provider in the 75th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$68,000
Medicare patients
337
Services billed
4,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate24$76,424
GocovriAmantadine Hcl12$39,111
Aimovig AutoinjectorErenumab-Aooe43$29,118
Nurtec OdtRimegepant Sulfate23$24,825
Emgality PenGalcanezumab-Gnlm24$21,852
RytaryCarbidopa/Levodopa17$21,550
UbrelvyUbrogepant19$18,952
QuliptaAtogepant12$12,812
Levetiracetam185$5,950
Lacosamide42$5,460
Pyridostigmine Bromide24$5,386
Carbidopa-Levodopa ErCarbidopa/Levodopa95$3,672
Rivastigmine43$3,671
Carbidopa-LevodopaCarbidopa/Levodopa246$3,571
Gabapentin260$3,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$373$76,42424 claims
MDD US Operations, LLCGocovri$27$39,11112 claims
AbbVieUbrelvy, Qulipta$891$31,76431 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$450$26,93641 claims
PfizerNurtec Odt$33$24,82523 claims
Upsher-smith Laboratories LLCTopiramate$213$616103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 702 neurology providers in Ohio.

Other neurology in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →